title: Role of Mid-induction Peripheral Blood Minimal Residual Disease Detection in Pediatric B-Lineage Acute Lymphoblastic Leukemia.
abstract: OBJECTIVE
  To study the role of mid-induction (day 15) peripheral blood minimal residual disease (PB-MRD) detection in pediatric B- lineage acute lymphoblastic leukemia (B-ALL).
  
  
  METHODS
  Prospective.
  
  
  METHODS
  Tertiary-care center.
  
  
  METHODS
  40 consecutively-diagnosed treatment-naive, pediatric B-ALL patients.
  
  
  METHODS
  National Cancer Institute (NCI) standard risk patients were given three drug induction regimen comprising vincristine, L-asparginase and prednisolone; NCI high-risk patients were supplemented with daunorubicin.
  
  
  METHODS
  Day 15 PB-MRD and bone marrow MRD (BM-MRD) analyzed by six color flow cytometry.
  
  
  RESULTS
  The sensitivity of day 15 PB-MRD to identify concurrent day 15 BM-MRD positivity was 64%, with 100% specificity. The positive and negative predictive values were 100% and 62.5%, respectively. PB-MRD was positive in 67% of relapsed patients.
  
  
  CONCLUSIONS
  BM-MRD is a well-established prognostic factor in B-ALL. We suggest, day 15 PB-MRD could be considered as an early, minimally invasive and easily accessible MRD screening option.
authors.affiliation: Department of Hematology and *Pediatric Hematology-Oncology Unit, PGIMER, Chandigarh, India. Correspondence to: Dr Man Updesh Singh Sachdeva, Additional Professor, Department of Hematology, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India. drmanupdeshpgi@yahoo.co.in.
authors.forename: Karthik
authors.initials: K
authors.lastname: Bommannan
authors.forename: Man Updesh
authors.initials: MU
authors.lastname: Singh Sachdeva
authors.forename: Neelam
authors.initials: N
authors.lastname: Varma
authors.forename: Parveen
authors.initials: P
authors.lastname: Bose
authors.forename: Deepak
authors.initials: D
authors.lastname: Bansal
mesh_terms: D001854:Bone Marrow Cells / Q000166:cytology; D002648:Child; D002675:Child, Preschool; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D008297:Male; D018365:Neoplasm, Residual / Q000175:diagnosis*; D015452:Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / Q000175:diagnosis* / Q000628:therapy*; D011237:Predictive Value of Tests; D011379:Prognosis; D011446:Prospective Studies